What I know is that in July 2019 is when we were told, that Rothchild was engaged by RVX to pursue U. S. listing. The share price at that time was ~$2.90 CAN.

What followed in May 2019 was the $4.00 CAN share offering. Share price went as high as $4.95 CAN. The hype was building up toward a successful BOM and a potential U.S. listing, so the $4.00 offering seemed reasonable.

We all know what followed. Sept 2019 BOM did not meet the top line and the share price went down to ~$0.50.

We closed yesterday at $0.47 CAN. A successful COVID 19 trial is what's needed for the share price to get back to respectability to cement a financing partner for BOM2. I'm not sure what else would get us there.

IMO ... Koo